Harrow Health - HROW Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month target prices for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $24.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.

Harrow Health's stock was trading at $14.76 at the start of the year. Since then, HROW stock has increased by 30.4% and is now trading at $19.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our HROW earnings forecast.

Harrow Health, Inc. (NASDAQ:HROW) posted its quarterly earnings data on Monday, November, 14th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.08. The firm earned $22.82 million during the quarter, compared to analysts' expectations of $23.39 million. Harrow Health had a negative net margin of 25.50% and a negative trailing twelve-month return on equity of 11.57%.

Harrow Health issued an update on its FY 2023 earnings guidance on Monday, January, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $117.72 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Harrow Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acuitas Investments LLC (0.88%), Westside Investment Management Inc. (0.70%), B. Riley Securities Inc. (0.58%), Mendota Financial Group LLC (0.07%), Bailard Inc. (0.04%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HROW stock can currently be purchased for approximately $19.24.

Harrow Health (NASDAQ:HROW) has a market capitalization of $520.83 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 182 workers across the globe.

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.